Microbiome composition for the treatment of metabolic disorders rheumatoid arthritis
A microbiome composition with specific strains addresses arthritis and metabolic disorders by inhibiting joint damage and regulating immune cells, enhancing mitochondrial function, and balancing gut flora, providing a safer alternative to TNF antagonists.
Patent Information
- Application Number
- KR1020220190507
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-01-03
- Filing Date
- 2022-12-30
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-12-30
AI Technical Summary
There is a rising prevalence of arthritis accompanied by metabolic disorders, particularly rheumatoid arthritis, which is exacerbated by metabolic abnormalities such as obesity, and current treatments like TNF antagonists have limitations including side effects and inefficacy, necessitating a safer and more effective approach.
A food or pharmaceutical composition comprising a microbiome with specific strains such as Virophylla (Bilophila sp.), Ackermencia (Akkermansia sp.), Faecalibacterium (Faecalibacterium sp.), and Disulfovifrio (Desulfovibrio sp.) or Bacteroides (Bacteroides sp.) to inhibit joint damage, increase Treg expression, and suppress the expression of immune cells like Th17, Th1, and Th2.
The microbiome composition reduces arthritis indices, protects against joint damage, enhances mitochondrial function, regulates gut microbiota, and suppresses IL-17 expression, effectively managing rheumatoid arthritis associated with metabolic disorders.
Smart Images

Figure 112022142396610-PAT00003_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a microbiome composition for treating metabolic disorders of rheumatoid arthritis. Background Technology
[0002] Despite growing awareness of obesity and global efforts to understand its causes and respond to it, obesity is on an accelerating upward trend (Mitchell et al., Implications for female fertility and obesity. Reproduction. 2005;130:583-97). According to the results of the 2007 National Health and Nutrition Survey, the proportion of the obese population in Korea has increased by 3% annually over the past five years, and the current obesity rate is 32.7% of the total population (33.1% for men and 32.2% for women). By age group, the average rate for the middle-aged is 44%, which is double that of the young adult population (22%). With the increase in diseases caused by obesity, the socioeconomic cost is estimated to reach 1.8239 trillion won as of 2007.
[0003] As the problem of obesity becomes more serious, the perception that obesity itself is a disease is spreading. The progression of obesity can typically be determined by whether a person is overweight, or specifically by an increase in body fat in specific areas (e.g., abdominal obesity). It is reported that individuals classified as obese—that is, obese people—have higher prevalence and mortality rates compared to other diseases, and compared to people with normal weight, the mortality rate from diabetes is four times higher, from mild liver disease is two times higher, from cerebrovascular disease is 1.6 times higher, and from coronary artery disease is 1.8 times higher.
[0004] Obesity is a serious chronic syndrome with various causes characterized by the excessive accumulation of fat. The goals of obesity treatment are broadly twofold: first, to reduce body weight by burning excess fat, and second, to improve metabolic imbalances. Patients with abdominal obesity are often associated with pathological conditions such as Syndrome X (insulin resistance, type 2 diabetes, hypertension, and lipid metabolism disorders) and act as strong risk factors for early atherosclerosis, ischemic heart disease, and cerebrovascular disease.
[0005] Immunological diseases are conditions in which components of the mammalian immune system cause, mediate, or otherwise contribute to pathological conditions in mammals; in particular, inflammatory disorders are one of the most important health issues worldwide. Inflammation is generally a localized protective response of body tissues against host invasion by external substances or harmful stimuli. Causes of inflammation can be infectious agents such as bacteria, viruses, and parasites; physical causes such as burns or radiation exposure; chemicals such as toxins, drugs, or industrial agents; immunological responses such as allergies and autoimmune reactions; or conditions associated with oxidative stress.
[0006] Inflammation is characterized by pain, reddening, swelling, fever, and the ultimate loss of function in the infected area. These symptoms are the result of a series of complex interactions occurring among the cells of the immune system. Cellular responses consequently generate an interaction network of various groups of inflammatory mediators: proteins (e.g., cytokines), enzymes (e.g., proteases, peroxidases), major basic proteins, adhesion molecules (ICAM, VCAM), lipid mediators (e.g., eicosanoids, prostaglandins, leukotrienes, platelet-activating factor (PAF)), and reactive oxygen species (e.g., hydroperoxide, superoxide anion O2-, nitric oxide (NO), etc.). However, most of these inflammatory mediators are also regulators of normal cellular activity. Therefore, a deficiency in the inflammatory response leads to uncontrolled damage (i.e., infection) to the host, and thus chronic inflammation causes inflammatory diseases mediated partly by the overproduction of several of the aforementioned mediators. Furthermore, autoimmune diseases, a type of immune disorder, are characterized by the immune system attacking its own organs to trigger a spontaneous response. These responses are attributed to the recognition of autoantigens by T lymphocytes, thereby Fluid-phase (autoantigen generation) and cellular-phase (increased cytotoxic activity of lymphocytes and macrophages) immune responses are triggered.
[0007] Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine involved in host defense, inflammation, apoptosis, lymphocyte stimulation, bone metabolism, TB lymphocyte interactions, lymphoid development, and the activation of immune cell functions. In particular, it plays the most critical role in the inflammatory response of rheumatoid arthritis and is associated with irreversible joint damage and the destruction of bone and cartilage. It was developed based on findings similar to rheumatoid arthritis observed in TNF-α transgenic mice and improvements shown with TNF-α receptor-based TNFR2-Fc and mAb treatments. TNF antagonists are approved for use not only in rheumatoid arthritis but also in juvenile arthritis, ankylosing spondylitis, and psoriatic arthritis. However, continuous administration of TNF antagonists is often not possible due to various reasons during use. According to one study, 21–35% of patients discontinued treatment after one year, with the causes being, in order, insufficient response, loss of response, and side effects. Safety issues regarding TNF antagonists have been evaluated post-marketing, and concerns have been raised regarding infections, malignancies, demyelinating disorders, aplastic anemia, congestive heart failure, and vasculitis. Injection site reactions were the most common side effects (20–40%); infliximab showed a low frequency of hypersensitivity reactions, but when they occurred, they were more severe, and the frequency of bacterial and opportunistic infections increased. Additionally, since tuberculosis can develop within several months of starting treatment due to the activation of latent tuberculosis, screening for latent tuberculosis and appropriate treatment are recommended prior to the initiation of therapy. It has been reported that antinuclear antibodies or anti-dsDNA antibodies may appear during TNF antagonist treatment, although the frequency was lower when administered concomitantly with MTX. Serious refractory status has been reported, with malignancies or lymphomas occurring in clinical trials of rheumatoid arthritis patients using TNF antagonists.
[0008] Recently, "arthritis accompanied by metabolic disorders," which results from impaired immune function due to metabolic abnormalities such as obesity, is on the rise. As the proportion of patients with metabolic disorders within the total population increases, the prevalence of arthritis accompanied by metabolic disorders is also on the rise. The problem to be solved
[0009] The objective of the present invention is to provide a food composition for the prevention or improvement of arthritis accompanied by metabolic abnormalities, comprising a microbiome as an active ingredient.
[0010] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient.
[0011] Another objective of the present invention is to provide a composition comprising a microbiome as an active ingredient to an individual, comprising the step of administering a composition comprising a microbiome to an individual, a group of arthritis patients with metabolic disorders, a genus of Virophylla ( Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. Increases ) and Disulfovifrio species ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. It is to provide a method to reduce ).
[0012] Another objective of the present invention is a composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient, wherein
[0013] The above composition is,
[0014] 1) Inhibit joint damage and
[0015] 2) Increases Treg expression, and
[0016] 3) Provides a composition that inhibits the expression of immune cells selected from the group consisting of Th17, B17, Th1, and Th2. means of solving the problem
[0017] To achieve the above objective, the present invention provides a food composition for the prevention or improvement of arthritis accompanied by metabolic abnormalities, comprising a microbiome as an active ingredient.
[0018] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient.
[0019] In addition, the present invention comprises the step of administering a composition containing a microbiome as an active ingredient to an individual; a group of arthritis patients with metabolic disorders, including a genus of Virophylla ( Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. Increases ) and Disulfovifrio species ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. Provides a method to reduce ).
[0020] In addition, the present invention relates to a composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient, wherein
[0021] The above composition is,
[0022] 1) Inhibit joint damage and
[0023] 2) Increases Treg expression, and
[0024] 3) Provides a composition that inhibits the expression of immune cells selected from the group consisting of Th17, B17, Th1, and Th2. Effects of the invention
[0025] It was confirmed that the microbiome strain of the present invention reduces the arthritis index and induction rate and protects against joint damage in a mouse model accompanied by metabolic abnormalities. Furthermore, it was confirmed that it regulates the expression of Treg, Th17, B17, Th1, and Th2, enhances mitochondrial function, and suppresses the expression of IL-17. Additionally, it was confirmed that the administration of the microbiome regulates changes and balance in the gut microbiota. By confirming that the expression of Th17 and Treg is regulated and osteoclast differentiation is inhibited in PBMCs due to the changes and regulation of the gut microbiota resulting from the administration of the microbiome, it was confirmed that it is effective against rheumatoid arthritis accompanied by metabolic abnormalities, and thus can be usefully utilized in related industries. Brief explanation of the drawing
[0026] Figure 1 illustrates the experimental schedule for the production of an animal model and the administration of a microbiome according to the present invention. FIG. 2 shows the Acermencia mucinophilia of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Akkermansia mucinophila This is a diagram confirming the arthritis index and induction rate following the administration of ) (A: confirmation of arthritis index, B: confirmation of induction rate). FIG. 3 shows the Acermencia mucinophilia of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Akkermansia mucinophila This figure confirms the protective effect against joint damage following the administration of ) by H&E and Safranine O staining (A: staining results, B: quantification of staining results). FIG. 4 shows the Acermencia mucinophilia of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Akkermansia mucinophila This is a diagram confirming the expression of Treg following the administration of ). FIG. 5 shows the Acermencia mucinophilia of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Akkermansia mucinophila This is a diagram confirming the amount of ATP following the administration of ). FIG. 6 shows the Acermencia mucinophilia of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Akkermansia mucinophila This is a graph confirming the expression of IL-17 following the administration of ) by immunohistochemical staining (A: staining result, B: quantification of staining result). FIG. 7 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the arthritis index and induction rate following the administration of ) (A: confirmation of arthritis index, B: confirmation of induction rate). FIG. 8 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This figure confirms the protective effect against joint damage following the administration of ) by H&E and Safranine O staining (A: staining results, B: quantification of staining results). FIG. 9 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the expression of immune cells following the administration of ) by flow cytometry (A: flow cytometry results, B: quantification of analysis results). FIG. 10 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the amount of metabolites in the serum following the administration of ) (A: butyric acid quantification, B: acetic acid quantification). FIG. 11 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a graph confirming the ratio of intestinal flora following the administration of ) (A: Confirmation of Firmictes / Bacteroides ratio, B: Confirmation of relative ratio). FIG. 12A shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the changes in the intestinal flora following the administration of ) through intestinal flora analysis. FIG. 12B shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the increase or decrease in the intestinal flora following the administration of ). FIG. 12C shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the genus Faecalibacterium sp. strains by qRT-PCR following the administration of ). FIG. 13 shows the Faecalibacterium prosnitch of the present invention in an animal model of rheumatoid arthritis accompanied by metabolic abnormalities ( Faecalibacterium prausnitzii This is a diagram confirming the increase in butyrate-producing bacteria in the intestines following the administration of ). Fig. 14 shows Acromencia mucinophilia in PBMC ( Akkermansia mucinophila This is a diagram confirming the expression of Th17 following treatment by flow cytometry (A: flow cytometry results, B: quantification of expression results). Fig. 15 shows Acromencia mucinophilia in PBMC ( Akkermansia mucinophila This is a diagram confirming Treg expression according to treatment by flow cytometry (A: flow cytometry results, B: quantification of expression results). Fig. 16 shows Acromencia mucinophilia in PBMC ( Akkermansia mucinophila This is a diagram confirming the differentiation of osteoclasts following treatment (A: Differentiation confirmation result, B: Quantification of osteoclast differentiation). Specific details for implementing the invention
[0027] The present invention provides a pharmaceutical composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient.
[0028] The term "prevention" as used in this invention refers to any act of suppressing the symptoms of a specific disease or delaying its progression through the administration of the composition of this invention.
[0029] The term "improvement" as used in the present invention refers to any action that at least reduces parameters related to the condition being treated, such as the degree of symptoms.
[0030] In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in conventional food compositions.
[0031] Examples of the natural carbohydrates described above include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agents described above may advantageously use natural flavoring agents (taumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition described above and used as a functional food or added to various foods. Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, food products, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.
[0032] In addition, the above food composition may contain, in addition to the extract which is an active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.
[0033] The functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., for the purpose of preventing or treating arthritis accompanied by metabolic disorders. In the present invention, the term "health functional food composition" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body pursuant to Article 6727 of the Act on Health Functional Foods, and means consuming it for the purpose of obtaining effects useful for health uses, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of the present invention may include conventional food additives, and unless otherwise stipulated, suitability as a food additive is determined according to the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety. Items listed in the aforementioned "Food Additives Codex" include, for example, chemical synthetic compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Examples include natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sorghum pigment, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline additives for noodles, preservative preparations, and tar dye preparations. For example, a health functional food in tablet form may be produced by granulating a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives using a conventional method, and then adding a lubricant or the like and compression molding, or by directly compression molding the said mixture. In addition, the health functional food in tablet form may contain a binder or the like as needed. Among health functional foods in capsule form, hard capsules may be manufactured by filling a conventional hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules may be manufactured by filling a capsule base such as gelatin with a mixture of the active ingredient of the present invention mixed with additives such as excipients. The above soft capsule may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as needed.A health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., using a previously known method, and if necessary, it can be coated with sucrose or other coating agents, or the surface can be coated with a substance such as starch or talc. A health functional food in the form of a granule can be prepared by making a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., into a granular form using a previously known method, and may contain flavoring agents, stimulating agents, etc., if necessary.
[0034] According to one embodiment of the present invention, the microbiome is Ackermenia mucinophilia ( Akkermansia mucinophila ) or Pecalibacterium prosnitch ( Faecalibacterium prausnitzii It could be ).
[0035] According to one embodiment of the present invention, the arthritis may be rheumatoid arthritis.
[0036] According to one embodiment of the present invention, the metabolic disorder may be obesity.
[0037] According to one embodiment of the present invention, the microbiome may protect against joint damage, and the protection against joint damage may inhibit osteoclast differentiation.
[0038] According to one embodiment of the present invention, the microbiome may regulate immune cells, and the immune cells may be selected from the group consisting of Treg, Th17, B17, Th1, and Th2.
[0039] According to one embodiment of the present invention, regulating the immune cells may involve increasing the expression of Treg and suppressing the expression of immune cells selected from the group consisting of Th17, B17, Th1, and Th2.
[0040] According to one embodiment of the present invention, the microbiome may enhance the function of mitochondria, and the enhancement of mitochondria may increase the amount of ATP.
[0041] According to one embodiment of the present invention, the microbiome may inhibit the expression of IL-17.
[0042] According to one embodiment of the present invention, the microbiome may increase the amount of butyrate in the serum and decrease the amount of acetate in the serum.
[0043] According to one embodiment of the present invention, the microbiome may increase the ratio of Firmictes to Bacteroides.
[0044] According to one embodiment of the present invention, the microbiome may regulate the intestinal flora and may be of the genus Virophylla ( Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. Increasing ); or the disulfovifrio genus ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. It may reduce ).
[0045] According to one embodiment of the present invention, the microbiome may increase butyrate-producing bacteria, and the butyrate-producing bacteria are of the genus Roseburia ( Roseburia sp. ), genus Coprococcus ( Coprococcus sp. ), genus Oschylospira ( Oscillospira sp. ), genus Luminococcus ( Ruminococcus sp. ) and the genus Clostridium ( Clostridium sp. It may be an increase in the selected strain from a group consisting of ).
[0046] According to one embodiment of the present invention, the composition may inhibit the differentiation of osteoclasts.
[0048] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient.
[0049] The term "treatment" as used in this invention refers to any act of improving or beneficially altering the symptoms of a specific disease through the administration of the composition of this invention.
[0050] In the present invention, the term "microbiome" refers to the entire genetic information of microorganisms inhabiting the human body or the microorganisms themselves. It is a compound word of "microbiota" (microorganisms inhabiting and coexisting with the human body) and "genome." It is known that the number of human microbiomes is more than twice the number of pure human cells and the number of genes is more than 100 times greater. Since the microbiome allows for the analysis of the principles of beneficial and harmful bacteria generation and the correlation between diseases, it refers to a field that can be widely utilized in research on the microbial environment within the human body, such as new drug development and the treatment of incurable diseases.
[0051] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase the effect.
[0052] The pharmaceutical composition according to the present invention may be prepared in a form in which an active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0053] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions, each according to conventional methods.
[0054] When formulating, the product may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the active ingredient. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may contain various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.
[0055] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.
[0056] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the subject, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.
[0058] In addition, the present invention comprises the step of administering a composition containing a microbiome as an active ingredient to an individual; a group of arthritis patients with metabolic disorders, including a genus of Virophylla ( Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. Increases ) and Disulfovifrio species ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. Provides a method to reduce ).
[0060] In addition, the present invention relates to a composition for the prevention or treatment of arthritis accompanied by metabolic disorders, comprising a microbiome as an active ingredient, wherein
[0061] The above composition is,
[0062] 1) Inhibit joint damage and
[0063] 2) Increases Treg expression, and
[0064] 3) Provides a composition that inhibits the expression of immune cells selected from the group consisting of Th17, B17, Th1, and Th2.
[0066] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.
[0068] <실시예 1> 아이이상 사랑의의 사랑보드이스 아이스트이스
[0069] To construct the animal model of metabolic arthritis according to the present invention, 7-week-old male DBA1 / J normal mice were given a high-fat diet of 60 kcal free-feeding starting one week prior to inducing arthritis, and the high-fat diet was administered until the end of the experiment. After one week of feeding the high-fat diet, 100 μg of Type II collagen mixed with Complete Freud's Adjuvant (CFA) was injected into the tail cuticle (first immunization), and two weeks later, the same Type II collagen mixed with an equal amount of Incomplete Freud's Adjuvant (IFA) was injected into the tail (second immunization) to construct the animal model of metabolic arthritis. In the animal model with induced metabolic arthritis, the microbiome of the present invention, Ackermenia mucinifera ( Akkermansia mucinophila ) to, second immunization after 1 week 1x10 10 The subjects were classified into the Akkermansia group by orally administering the substance at the concentration of / mice six times a week until the end of the experiment (see Figure 1). As a control group, a Vehicle group was used in which metabolic dysarthritis was induced and physiological saline was injected. Subsequently, the arthritis score was evaluated based on the following criteria, and the incidence of arthritis was calculated.
[0070] 0 points: No deficiency or swelling.
[0071] 1 point: Mild swelling and redness localized to the foot or ankle joint
[0072] 2 points: Mild swelling and redness extending from the ankle joint to the metatarsals
[0073] 3 points: Moderate swelling and redness extending from the ankle joint to the tarsal bones
[0074] 4 points: Swelling and redness from the ankle to the entire leg
[0076] As a result, as shown in Figure 2, it was confirmed that the arthritis score and incidence were significantly reduced in the Akkermansia group compared to the Vehicle group.
[0078] <실시예 2> 아이니시이 뮤시니한다의 사랑의 아이트 한국어
[0079] We intended to determine whether Acermencia mucinifilia, the microbiome of the present invention, protects against joint damage in rheumatoid arthritis accompanied by metabolic abnormalities. Specifically, the mice of Example 1 were humanely sacrificed at the end of the experiment, joint tissues were obtained, and sections were prepared. The joint tissue portions of the prepared sections were stained with Hematoxylin & Eosin (H&E) and Safranin O stains to confirm joint damage and cartilage damage, which were then quantified and compared.
[0081] As a result, as shown in Figure 3, compared to the Vehicle group, the Akkermansia group ( A. muciniphila It was confirmed that joint damage and cartilage damage were inhibited, and that the related inflammation score, bone damage, and cartilage damage indices were significantly reduced.
[0083] <Example 3> Confirmation of the Treg expression regulatory effect of Acermencia mucinophilia
[0084] We intended to determine whether Acermencia mucinifilia of the present invention increases the expression of regulatory T cells (Treg) capable of regulating autoimmunity. Specifically, in Example 2 above, a spleen was extracted from a humanely sacrificed mouse and flow cytometry was performed to confirm the expression of Treg.
[0086] As a result, as shown in Figure 4, compared to the Vehicle group, the Akkermansia group ( A. muciniphila It was confirmed that the expression of Treg significantly increased in ).
[0088] <Example 4> Confirmation of Mitochondrial Function-Enhancing Effect of Acermencia mucinophilia
[0089] It has been reported that mitochondrial function decreases in rheumatoid arthritis accompanied by metabolic abnormalities, so we confirmed whether Acermencia mucinifera of the present invention enhances mitochondrial function. Specifically, in order to confirm the amount of ATP resulting from the enhancement of mitochondrial function, the amount of ATP was confirmed from the spleen of the mouse sacrificed in Example 2 above.
[0091] As a result, as shown in Figure 5, it was confirmed that the amount of ATP decreased in the Vehicle group compared to the wild type (WT), and the Akkermansia group ( A. muciniphila It was confirmed that the amount of reduced ATP in the Vehicle group significantly increased.
[0093] <Example 5> Confirmation of IL-17 Inhibition by Acermencia mucinophilia
[0094] We intended to determine whether the microbiome of the present invention, Acermencia mucinifilia, suppresses the expression of IL-17, a factor associated with rheumatoid arthritis accompanied by metabolic abnormalities. Specifically, the joint tissue portion of the mouse sacrificed in Example 2 was sectioned, and the expression of IL-17 was confirmed by staining it with immunohistochemical staining.
[0096] As a result, as shown in Fig. 6, compared to the Vehicle group, the Akkermansia group ( A. muciniphila It was confirmed that IL-17 expression was significantly reduced in ).
[0098] <Example 6> Confirmation of the effects of Faecalibacterium prosnitch in an animal model of metabolic arthritis
[0099] The Faecalibacterium prosnitch of the present invention ( Faecalibacterium prausnitziiTo determine whether ) is effective in rheumatoid arthritis accompanied by metabolic abnormalities, rheumatoid mice accompanied by metabolic abnormalities were used in the same manner as in Example 1 above, and live bacteria (Faecali live group, Flive) and dead bacteria (Faecali dead group, Fdead) were administered respectively to check the arthritis score and incidence.
[0101] As a result, as shown in Figure 7, it was confirmed that the arthritis score and incidence were significantly reduced in both the Faecali live group and the Faecali dead group compared to the Vehicle group.
[0103] <Example 7> Confirmation of Joint Protective Effect of Faecalibacterium prosnitch
[0104] In order to determine whether the microbiome of the present invention, *Fecalibacterium prosnitch*, protects against joint damage, the mice of Example 6 were humanely sacrificed at the end of the experiment, joint tissues were obtained and sections were prepared, and joint inflammation, bone damage, and cartilage damage indices were checked using H&E and Safranin O staining.
[0106] As a result, as shown in Figure 8, it was confirmed that joint damage and cartilage damage were inhibited in both the Faecali ilve group and the Faecali dead group compared to the Vehicle group, and that the inflammation index, bone damage, and cartilage damage index were significantly reduced.
[0108] <Example 8> Confirmation of Immune Cell Regulatory Effect of Faecalibacterium prosnitch
[0109] In order to determine whether the microbiome of the present invention, *Fecalibacterium prosnitch*, regulates immune cells, the spleen of the mouse sacrificed in Example 6 was extracted, and the expression of Th17, B17, Th1, and Th2 in the spleen cells was analyzed by flow cytometry.
[0111] As a result, as shown in Figure 9, compared to the Vehicle group, the expression of Th17, B17, Th1, and Th2 was significantly reduced in both the Faecali live group and the Faecali dead group, and in particular, it was confirmed that the expression of Th17, B17, and Th1 was further reduced in the Faecali live group compared to the Faecali dead group.
[0113] <Example 9> Confirmation of Metabolite Regulation by Faecalibacterium prosnitch
[0114] In order to determine whether the microbiome of the present invention, *Fecalibacterium prosnitch*, regulates the amounts of butyrate and acetate, which are serum metabolites associated with metabolic abnormalities, whole blood was collected from the mice sacrificed in Example 6, and the amounts of butyrate and acetate were determined from the serum using the HPLC method.
[0116] As a result, as shown in Figure 10, compared to the Vehicle group, the amount of butyric acid in the serum of the Faecali live group was significantly increased and the amount of acetic acid was significantly decreased, confirming that metabolic abnormalities were controlled.
[0118] <Example 10> Confirmation of the intestinal microbiome regulating effect of Faecalibacterium prosnitch
[0119] <10-1> Checking Total Ratio Adjustment
[0120] Since metabolic abnormalities can lead to an imbalance of beneficial / harmful bacteria in the gut flora or the metabolism-related microbiome, we sought to verify whether the Faecalibacterium prosnitch of the present invention could regulate the gut flora and restore it to normal. Specifically, the large intestine of the sacrificed mouse from Example 6 was obtained, and from the obtained large intestine, the ratio of Firmicutes, which contain a large number of beneficial bacteria, and Bacteroides, which contain a large number of anaerobic harmful bacteria, was determined, and the relative abundance of all gut flora was determined.
[0122] As a result, as shown in Figure 11, the ratio of Firmicutes to Bacteroides in the Faecali live group was significantly increased compared to the Vehicle group, and it was confirmed that the ratio of Firmicutes increased in relative abundance.
[0124] <10-2> Confirmation of changes in the fungal colony
[0125] In order to determine whether the Fecalibacterium prosnitch of the present invention induces changes in the intestinal flora, the Fecal obtained in Example 10-1 above was analyzed.
[0126] After the experiment was completed, fecals were collected and stored at -70°C until analysis. For metagenomic analysis, bacterial genomic DNA isolation, microorganism-specific 16S rRNA gene amplification, Next Generation Sequencing (NGS), and gut microbiota analysis and profiling were performed. The isolated gDNA was amplified using primers designed for regions containing the V3 and V4 variant regions of the bacteria-specific 16S rRNA sequence. Two PCR cycles were then performed to construct a library by attaching index sequences to distinguish the samples, followed by sequencing using Illumina's Miseq. The decoded sequences were analyzed using the bioinformatics tools Quantitative Insights into Microbial Ecology 2 (QIIME 2) and Lefse, while gut microbiota profiling was performed using Prism and R for statistical analysis.
[0128] As a result, as shown in Fig. 12, changes in the gut microbiota were confirmed in mice with metabolic disorders and in the Faecali live group (Fig. 12A). Specifically, in the Faecali live group, Bilophila and Akkermansia were significantly increased, while Desulfovibrio and Bacteroides were significantly decreased (Fig. 12B). In addition, Faecalibacterium was significantly increased (Fig. 12C).
[0130] <10-3> Confirmation of changes in butanoic acid-producing bacteria
[0131] In order to determine whether the Faecalibacterium prosnitch of the present invention increases the butyrate-producing strain, the ratio of butyrate-producing strains was determined based on the results of Example 10-2 above.
[0133] As a result, as shown in Figure 13, compared to the Vehicle group, it was confirmed that strains of the genera Roseburia, Coprococcus, Oscillophira, Ruminococcus, and Clostridium, which produce butanoic acid, were significantly increased in the Faecali live group.
[0135] <Example 11> Confirmation of cell-regulating effects of Acermencia mucinophilia (in vitro)
[0136] <11-1> Confirmation of Immune Cell Regulation
[0137] We confirmed whether Akermencia mucinifilia, the microbiome of the present invention, can regulate immune cells in actual patients with rheumatoid arthritis accompanied by metabolic disorders. Specifically, peripheral blood mononuclear cells (PBMCs) derived from healthy individuals were stimulated under anti-CD3 conditions, which are differentiation conditions for a pathological state, through T cell activation conditions, and at this time A. muciniphilaIn cells obtained 72 hours after treatment, CD4 and IL-17 were stained and flow cytometry was performed to confirm the expression of Th17 cells, which are immune cells causating rheumatoid arthritis, and Treg cells, which are immune cells regulating rheumatoid arthritis.
[0139] As a result, as shown in Fig. 14, it was confirmed that Acermencia mucinifilia significantly inhibits Th17 cells, which are elevated in expression in PBMCs. In addition, it was confirmed that it can improve the symptoms of rheumatoid arthritis associated with metabolic disorders by significantly increasing the expression of Treg in PBMCs (Fig. 15).
[0141] <11-2> Confirmation of Osteoclast Differentiation Inhibition
[0142] We investigated whether Acermencia muciniphila, the microbiome of the present invention, inhibits the differentiation of osteoclasts associated with bone damage in rheumatoid arthritis accompanied by metabolic disorders. Specifically, precursor cells, which are the precursors of osteoclasts, were first generated by treating PBMCs isolated from healthy individuals with 100 ng / ml of M-CSF, a macrophage proliferation stimulating factor. Subsequently, the cells were treated with 30 ng / mL of RANKL, an osteoclast differentiation factor, and 25 ng / ml of M-CSF, followed by the addition of 1 µg / mL of A. muciniphila and subsequent culture. While observing the cells until the completion of osteoclast differentiation, RANKL 30 ng / mL, M-CSF 25 ng / ml, and A. muciniphila 1 µg / mL were added at media replacement intervals of 3 to 4 days. After the completion of osteoclast differentiation, TRAP (Tartrate-resistant acid phosphatase), an osteoclast differentiation marker, was stained. Afterwards, the stained cells were counted to confirm osteoclast differentiation.
[0144] As a result, as shown in Figure 16, it was confirmed that when PBMC is treated with RANKL, differentiation into osteoclasts is promoted, and when treated with Acermensia mucinifera, differentiation into osteoclasts is inhibited, thus confirming that bone damage can be inhibited.
[0146] Accordingly, it was confirmed that the microbiome strain of the present invention reduces the arthritis index and induction rate and protects against joint damage in a mouse model accompanied by metabolic abnormalities. In addition, it was confirmed that it regulates the expression of Treg, Th17, B17, Th1, and Th2, enhances mitochondrial function, and suppresses the expression of IL-17. Furthermore, it was confirmed that the administration of the microbiome regulates changes and balance in the gut microbiota. Through the changes and regulation of the gut microbiota following the administration of the microbiome, it was confirmed that the expression of Th17 and Treg is regulated and osteoclast differentiation is inhibited in PBMCs, thereby confirming that it is effective against rheumatoid arthritis accompanied by metabolic abnormalities.
Claims
Claim 1 Akkermencia mucinophilia ( Akkermansia muciniphila A food composition for preventing or improving joint damage caused by arthritis accompanied by metabolic disorders, comprising ) as an active ingredient and inhibiting the differentiation of osteoclasts, wherein the arthritis is rheumatoid arthritis and the metabolic disorder is obesity. Claim 2 In claim 1, the food composition is Faecalibacterium prosnitch ( Faecalibacterium prausnitzii A food composition for the prevention or improvement of joint damage caused by arthritis accompanied by metabolic disorders, which additionally includes ). Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that regulates immune cells. Claim 8 A food composition according to claim 7, wherein the immune cells are selected from the group consisting of Treg, Th17, B17, Th1, and Th2. Claim 9 A food composition according to claim 7, wherein regulating the immune cells increases the expression of Treg. Claim 10 A food composition according to claim 7, wherein regulating the immune cells suppresses the expression of immune cells selected from the group consisting of Th17, B17, Th1, and Th2. Claim 11 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that enhances the function of mitochondria. Claim 12 A food composition according to claim 11, wherein the enhancement of the function of the above mitochondria is an increase in the amount of ATP. Claim 13 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that inhibits the expression of IL-17. Claim 14 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that increases the amount of butyrate in the serum. Claim 15 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that reduces the amount of acetic acid (Acetate) in the serum. Claim 16 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that increases the ratio of Firmictes / Bacteroides. Claim 17 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila ) is a food composition that regulates the intestinal flora. Claim 18 In Clause 17, regulating the above intestinal flora is the genus Virophylla ( Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. A food composition that increases ). Claim 19 In Clause 17, regulating the above intestinal flora is the genus Disulfovifrio ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. A food composition that reduces ). Claim 20 In claim 1, the above Akermencia mucinophilia ( Akkermansia muciniphila A food composition that increases butyrate-producing bacteria. Claim 21 In Clause 20, the above butanoic acid-producing bacteria are of the genus Roseburia ( Roseburia sp. ), genus Coprococcus ( Coprococcus sp. ), genus Oschylospira ( Oscillospira sp. ), genus Luminococcus ( Ruminococcus sp. ) and the genus Clostridium ( Clostridium sp. A food composition that increases a strain selected from a group consisting of ). Claim 22 delete Claim 23 Akkermencia mucinophilia ( Akkermansia muciniphila A pharmaceutical composition for the prevention or treatment of joint damage caused by arthritis accompanied by metabolic disorders, comprising ) as an active ingredient and inhibiting the differentiation of osteoclasts, wherein the arthritis is rheumatoid arthritis and the metabolic disorder is obesity. Claim 24 In claim 23, the above pharmaceutical composition is Faecalibacterium prosnitch ( Faecalibacterium prausnitzii A pharmaceutical composition that additionally includes ). Claim 25 Akkermencia mucinophilia ( Akkermansia muciniphila A step of administering a composition containing ) as an active ingredient to an individual excluding humans; comprising a Virophylla genus (in a group of arthritis patients excluding humans with metabolic disorders) Bilophila sp. ), Ackermencia genus ( Akkermansia sp. ) or the genus Faecalibacterium ( Faecalibacterium sp. Increases ) and Disulfovifrio species ( Desulfovibrio sp. ) or genus Bacteroides ( Bacteroides sp. A method for reducing ), wherein the arthritis is rheumatoid arthritis and the metabolic disorder is obesity. Claim 26 In claim 25, the above composition is Faecalibacterium prosnitch ( Faecalibacterium prausnitzii A method that additionally includes ).
Citation Information
Patent Citations
Use of Akkermansia muciniphila to treat inflammatory conditions
JP2018534277A
Use of akkermansia for treating metabolic disorders
KR1020150093711A
